Natco tumbles on Copaxone ruling amid fears of thinning opportunity
This article was originally published in Scrip
Executive Summary
Natco Pharma fell sharply on Indian bourses after the US Supreme Court on 20 January ruled in favour of Teva Pharmaceutical Industries and remanded a case concerning the Israeli firm's money-spinning multiple sclerosis drug, Copaxone (glatiramer acetate), back to the US Court of Appeals for the Federal Circuit.